Core Insights - The company reported a decline in net profit attributable to shareholders by 23.1% year-on-year for Q3 2025, indicating overall performance pressure [1] - The company focuses on the integration of cosmetic and pharmaceutical sectors, leveraging a "5+N" core technology matrix to enhance future performance [1] Financial Performance - For Q1-Q3 2025, the company achieved revenue of 2.6 billion yuan, down 7.3% year-on-year, with a net profit of 140 million yuan, a decrease of 17.2% [1] - In Q3 alone, revenue was 810 million yuan, down 8.0%, and net profit was 30 million yuan, down 23.1% [1] - The overall gross margin for Q1-Q3 2025 was 51.5%, a slight decrease of 0.4 percentage points [2] Business Segment Analysis - Cosmetics segment revenue was 1.57 billion yuan, down 8.2%, with a gross margin of 61.2%, a decrease of 1.1 percentage points; notable performances included a 19.5% increase in revenue for the Yilian brand [2] - Pharmaceutical segment revenue was 310 million yuan, down 17.5%, but gross margin improved by 1.8 percentage points to 52.3% [2] - Raw materials segment revenue increased by 11.2% to 280 million yuan, with a gross margin of 40.3%, up 0.9 percentage points; pharmaceutical-grade raw material sales surged by 107.8% year-on-year [2] Brand and Strategic Developments - The Yilian brand maintained growth, with a 28% increase in sales for the spray product line in Q1-Q3 2025; a new product launch achieved significant sales during a major shopping event [3] - The company is advancing its raw material strategy, achieving regulatory approvals for new ingredients and enhancing its product offerings in the health and wellness sector [3] - The company is also innovating in traditional Chinese medicine, collaborating with established brands to develop new products [3]

Core Insights - The article highlights the impressive display of Furuida, a subsidiary of Lushang Group, at the third Chain Expo, showcasing its innovations in the beauty and health sectors, particularly in traditional Chinese medicine modernization and synthetic biology breakthroughs [1][10] - Furuida's achievements reflect Lushang Group's strategic focus on technological innovation and collaboration with research institutions like the Shandong Academy of Pharmaceutical Sciences [1][9] Product Matrix: Breakthroughs from Raw Materials to End Solutions - Furuida's exhibition presented a comprehensive range of products, integrating traditional Chinese medicine with modern technology, particularly addressing sensitive skin issues through advanced extraction techniques [5] - The company has made significant advancements in synthetic biology, particularly with its royal jelly acid series, which targets aging skin by utilizing engineered bacteria for efficient production [5] Green and Sustainable Practices - Furuida emphasizes sustainability throughout its supply chain, producing raw materials that meet international certification standards and utilizing biodegradable packaging that reduces degradation time by over 60% compared to traditional plastics [6] End Products and Light Medical Aesthetic Solutions - The company offers a wide array of products, including the Yilian hyaluronic acid series and the Ai'er Doctor micro-ecological skincare line, which have gained popularity and recognition for their innovative approaches to skin health [7] R&D Core: From Laboratory to Market - Furuida has established a robust R&D system that spans basic research to industrial application, particularly excelling in the field of hyaluronic acid with patented technologies that enhance its market competitiveness [8] Lushang Innovation Ecosystem: From Single Point Breakthroughs to Systemic Empowerment - Furuida's innovations are part of Lushang Group's broader strategy to integrate research and development with industry, supported by the Shandong Academy of Pharmaceutical Sciences, which has made significant contributions to the company's technological advancements [9] Conclusion: Advancing China's Global Influence in Manufacturing - Furuida's success at the Chain Expo and its global supply chain strategies illustrate the upgrading path of China's beauty and health industry, driven by technological innovation and sustainable practices [10]